What does Kaiser Permanente Southern California require to renew Wegovy?

Liver Disease (MASH) — Applies to Employer plans. Renewal requires: (1) disease is stable or improved from baseline; (2) no concurrent use of Rezdiffra, GLP-1 agonist, or GLP-1/GIP agonist; (3) biopsy or non-invasive test (elastography or ELF) demonstrating fibrosis stage 2 or 3 — note the renewal fibrosis test does NOT specify a 12-month lookback (only the initial criteria do). Specialist prescribing/consultation and lifestyle program enrollment are NOT re-verified at renewal.

How current is this information?

The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Kaiser Permanente Southern California coverage for

Does Kaiser Permanente Southern California cover Wegovy for Liver Disease (MASH)?

Yes. Kaiser Permanente Southern California covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.

Policy document

Standard Commercial Guidelines 6 1 26 Excerpted

Kaiser Permanente Southern California · PA policy · Employer

Effective June 1, 2026. Verified June 5, 2026.

View PDF Download Original insurer source

Employer: Covered with requirements. See the qualification pathways below.

Earliest policy review June 5, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Liver Disease (MASH) (1 plan type)

Applies to Employer plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

MASH — Initial Approval

All of:

Age ≥ 18 years
Diagnosis of noncirrhotic MASH/NASH
Therapy prescribed by or in consultation with a hepatologist, gastroenterologist, or endocrinologist
Patient is enrolled in or has completed a lifestyle intervention (dietary, exercise, psychology)
Biopsy or non-invasive test (elastography or ELF testing) within the past 12 months demonstrating liver fibrosis stage 2 or 3
No concurrent use of Rezdiffra (resmetirom), another GLP-1 receptor agonist, or GLP-1/GIP receptor agonist

Documentation to bring

Documentation of age ≥ 18 years
Diagnosis of noncirrhotic MASH/NASH
Prescriber attestation or consultation note from hepatologist, gastroenterologist, or endocrinologist
Documentation of enrollment in or completion of a lifestyle intervention program (dietary, exercise, or psychology-based)
Liver biopsy or non-invasive test result (elastography/FibroScan or ELF blood test) within the past 12 months demonstrating fibrosis stage F2 or F3
Confirmation of no concurrent use of Rezdiffra (resmetirom), GLP-1 receptor agonist, or GLP-1/GIP receptor agonist

Approval and renewal

Renewal: Renewal requires: (1) disease is stable or improved from baseline; (2) no concurrent use of Rezdiffra, GLP-1 agonist, or GLP-1/GIP agonist; (3) biopsy or non-invasive test (elastography or ELF) demonstrating fibrosis stage 2 or 3 — note the renewal fibrosis test does NOT specify a 12-month lookback (only the initial criteria do). Specialist prescribing/consultation and lifestyle program enrollment are NOT re-verified at renewal.

Not covered when

Cirrhotic liver disease (noncirrhotic MASH/NASH only)
Concurrent use of Rezdiffra (resmetirom)
Concurrent use of another GLP-1 receptor agonist or GLP-1/GIP receptor agonist (tirzepatide products)

Policy note: Fibrosis must be stage 2 or 3 (F2–F3). The policy explicitly requires 'noncirrhotic' MASH/NASH, excluding cirrhotic patients. At renewal, the 12-month lookback on the fibrosis test is not explicitly re-stated; renewal only requires evidence of fibrosis stage 2 or 3 without a specified timeframe. The MASH confirmation methods list is inferred from the document's examples: 'elastography' maps to FibroScan VCTE and 'Enhanced Liver Fibrosis [ELF] testing' maps to ELF test; liver biopsy is also explicitly listed.

Policy effective June 1, 2026 · verified June 5, 2026 · source: Standard Commercial Guidelines 6 1 26 Excerpted · View policy document (PDF)

Open on its own page →

Questions people ask

Does Kaiser Permanente Southern California cover Wegovy?: Yes. Kaiser Permanente Southern California covers Wegovy for liver disease (MASH) with prior authorization. Other policy requirements and your plan's benefits also apply.
What does Kaiser Permanente Southern California require to renew Wegovy?: Liver Disease (MASH) — Applies to Employer plans. Renewal requires: (1) disease is stable or improved from baseline; (2) no concurrent use of Rezdiffra, GLP-1 agonist, or GLP-1/GIP agonist; (3) biopsy or non-invasive test (elastography or ELF) demonstrating fibrosis stage 2 or 3 — note the renewal fibrosis test does NOT specify a 12-month lookback (only the initial criteria do). Specialist prescribing/consultation and lifestyle program enrollment are NOT re-verified at renewal.
How current is this information?: The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Summary of Kaiser Permanente Southern California's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.